Dova Pharmaceuticals Inc logo

DOVA - Dova Pharmaceuticals Inc News Story

$28.04 0.0  0.0%

Last Trade - 11/11/19

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £9.83m
Position in Universe th / 6858

UPDATE 1-Dova Pharma's blood disorder drug gets FDA approval

Mon 21st May, 2018 4:43pm
(Adds details, background)
    May 21 (Reuters) - The U.S Food and Drug Administration said
on Monday it had approved Dova Pharmaceuticals Inc's  DOVA.O 
drug to treat low blood platelet count in chronic liver disease
(CLD) patients, who are scheduled to undergo a medical
procedure.
    The drug to treat thrombocytopenia belongs to a class of
treatments called thrombopoietin receptor agonists (TPO RA),
which stimulate platelet production, and is the first such
treatment to be approved by the FDA for CLD patients.
    Thrombocytopenia is a common complication seen in chronic
liver disease patients caused by a low blood platelet count,
which may result in severe bleeding.
    A blood platelet transplant is commonly recommended for
thrombocytopenia patients undergoing medical procedures such as
liver biopsy.
    "This drug may decrease or eliminate the need for platelet
transfusions, which are associated with risk of infection and
other adverse reactions," said Richard Pazdur, acting director
of the Office of Hematology and Oncology Products in the FDA's
Center for Drug Evaluation and Research.
    Japan-based Shionogi & Co Ltd  4507.T  is developing a
similar drug and an FDA decision is due by late August.
    Shares of Dova were halted on the Nasdaq.

 (Reporting by Manas Mishra and Sharnya G in Bengaluru; Editing
by Sai Sachin Ravikumar and Anil D'Silva)
 ((Manas.Mishra@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 806749 8325; Reuters Messaging:
manas.mishra.thomsonreuters.com@reuters.net))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.